CEL-SCI Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CVM American 2836 http://www.cel-sci.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CEL-SCI Corporation

CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension - Mar 8th, 2023 2:00 pm
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology - Mar 3rd, 2023 2:00 pm
CVM: BLA Filing Still on the Horizon - Feb 27th, 2023 10:26 am
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results - Feb 15th, 2023 2:00 pm
CVM: A New Year Ahead - Jan 3rd, 2023 4:57 pm
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments - Dec 28th, 2022 2:00 pm
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients - Nov 22nd, 2022 5:21 pm
CEL-SCI Corporation Issues Letter to Shareholders - Nov 22nd, 2022 2:00 pm
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment - Oct 17th, 2022 12:50 pm
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer - Sep 12th, 2022 1:00 pm
CVM: ClinicalTrials Submission - Aug 24th, 2022 9:45 am
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov - Aug 19th, 2022 12:45 pm
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results - Aug 15th, 2022 1:00 pm
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors - Aug 8th, 2022 12:45 pm
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten - Jul 14th, 2022 2:00 pm
CEL-SCI Corporation to Present at LD Micro Invitational - Jun 8th, 2022 1:00 pm
CVM: ASCO 2022: The Details Matter - Jun 8th, 2022 9:25 am
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO - Jun 7th, 2022 11:30 am
CEL-SCI Announces Publication of ASCO 2022 Abstracts - May 27th, 2022 1:00 pm
CVM: Second Quarter Fiscal Year 2022 Financial Results - May 19th, 2022 9:10 am